Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 1, 2010

Marco Polo Takes Over Biocortech’s Antidepressant for Treatment-Resistant Disease

  • France-based drug repositioning company Marco Polo Pharmaceuticals obtained rights to develop Biocortech’s eburnamine derivative, BC-19, for treatment-resistant depression.

    Biocortech says that the agreement is in line with its strategic shift toward the development of biomarkers and tests for psychiatric disorders. Marco Polo will thus take over all further clinical development of the drug as well as commercializaton or outlicensing to a commercialization partner. 

    BC-19 was previously being investigated in the areas of cerebral insufficiency and cognitive deficits, Biocortech explains. The firm says that studies showed that the drug had benefits as an antidepressant in patients with treatment-resistant depression. BC-19 could also represent the first disease-modifying therapy for depression, according to Biocortech, by restoring the function of deficient noradrenergic pathways terminating in the prefrontal cortex.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »